• Increase font size
  • Default font size
  • Decrease font size
home | about us | contact us
Search
Search Only:

Search Keyword immunocellular

Total: 50 results found.

... 442 9.51 ImmunoCellular Therapeutics 444  ...
... ImClone Systems 590 10.76 ImmunoCellular Therapeutics 593  ...
... MD, Ph.D. to its Board of Directors. ImmunoCellular Therapeutics (OTCBB: IMUC) today announced second quarter results for the period ended June 30, 2010. Omnicell, Inc., (Nasdaq:OMCL) a leading ...
LOS ANGELES--ImmunoCellular Therapeutics (OTCBB: IMUC) today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations ...
... and Tarceva(R), for anti-cancer therapy. The issued patent extends patent protection around menadione into 2026. ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that it has appointed Zvi Ram, ...
LOS ANGELES--ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that it has appointed Zvi Ram, M.D. and John Boockvar, M.D. to its Scientific Advisory Board. Dr. Ram is the Chairman of the Department ...
... 114 Glycotope 114 ImmunoCellular Therapeutics 114  ...
... more predictable procedures. The early, but encouraging results were presented June 12, 2010 at the Society of Vascular Surgery's 2010 Vascular Annual Meeting in Boston. ImmunoCellular Therapeutics (OTCBB: ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced ithas ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that Dr. Rahul Singhvi has been appointed to the company’s Board of Directors. Dr. Singhvi is currentlyhe President ...
... technology. The federal funding could accelerate the company’s clinical activities. ImmunoCellular Therapeutics (OTCBB: IMUC) announced that the U.S. Food and Drug Administration has granted orphan drug ...
LOS ANGELES--ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ICT-107, the company's dendritic cell-based ...
... antitumor activity against murine xenograft models of human colorectal cancer (CRC) established from both cell lines and primary human samples. ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) jumped ...
As subscribers to BioMedReports were alerted yesterday, a therapeutic brain cancer vaccine developed by ImmunoCellular Therapeutics Ltd (IMUC.OB) has shown that nearly half the patients were alive without ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that datarom a ...
16. Survival Data Watchlist Alert
(Premium Content/Subscriber Only Content)
We are hearing some interesting chatter about long term survival data which will be presented at ASCO by ImmunoCellular Therapeutics, Ltd. (IMUC.OB). The data is supposed to be quite impressive and we ...
... from The National Association of Boards of Pharmacy (NABP). ImmunoCellular Therapeutics. Ltd. or "IMUC" (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer ...
LOS ANGELES--ImmunoCellular Therapeutics. Ltd. or "IMUC" (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, issued the following Letter to Shareholders ...
... Active Learning Challenge were presented this past week at the 13th International Conference on Artificial Intelligence and Statistics, in Sardinia, Italy. ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it wil be ...
... Hemispherx has engaged Fountain with a plan to initiate this study during next year's flu season in various parts of China. ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancrs, ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, annonced ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC) announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer tretment ...
... served as the central electroencephalogram (EEG) reader for the study. The topline results of the study were the subject of a previous press release by Icagen. ImmunoCellular Therapeutics, Ltd. (OTCBB: ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, annonced ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended Decembr 31, ...
... pill-like administration of these newer therapies. The Cancer Immunotherapy Index includes Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), Immunocellular Therapuetics, Ltd. (OTCBB:IMUC), Dendreon (NASDAQ:DNDN), ...
...  rather than pill-like administration of these newer therapies. The Cancer Immunotherapy Index includes Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), Immunocellular Therapuetics, Ltd. (OTCBB:IMUC), ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, annonced ...
Could latest results mean that IMUC is close to securing a partnership? ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) announced today that its dendritic cell-based vaccination with cancer stem cells ...
... of Directors. ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received ...
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received ...
LOS ANGELES--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received ...
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, annonced ...
... further in the after hours session. ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that Manish Singh, Ph.D., President and CEO will be presenting at the 2010 BIO CEO & Investor Conference on ...
LOS ANGELES--ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that Manish Singh, Ph.D., President and CEO will be presenting at the 2010 BIO CEO & Investor Conference on Tuesday, February ...
... annualized 90% rate since its original creation by Mentor Capital twenty-nine weeks ago. The current ten CI Index companies that Mentor Capital has invested into are: Dendreon (NASDAQ:DNDN), Immunocellular ...
... meaning that each share is divided into two shares of the same class. ImmunoCellular Therapeutics (OTC.BB: IMUC) today announced the results of a study in which it was shown that certain specific antigens ...
... Immunotherapy Index. The ten companies that Mentor Capital has invested in include Immunocellular Therapuetics, Ltd. (OTCBB:IMUC), Dendreon (NASDAQ:DNDN), Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), ...
I had the opportunity last week to discuss the updated strategy and expected milestones for ImmunoCellular Therapeutics (OTC: IMUC.OB) in 2010 and beyond with CEO, Manish Singh, following the conclusion ...
... of progression-free survival status at 5.5 months from the date of first dose. The estimated study completion date is Nov 2010. ImmunoCellular Therapeutics (IMUC.OB) is developing an off-the-shelf (i.e. ...
... property (IP) / patent estate, and commercial potential include ImmunoCellular Therapeutics (IMUC.OB) and Celldex Therapeutics (NASDAQ: CLDX). Quantum Immunologics (QI) is a privately held company that ...
44. RxNews Recap for Monday 12-07-09
(Home Page/Home Page)
... New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia. ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is focused on the development of novel immune-based ...
... trial for arimoclomol in ALS patients $IMUC.OB / ImmunoCellular Notches Deal with MD Anderson for New Cancer Stem Cell Vaccine Target / http://hub.tm/QOmte Click here to follow me on twitter / mikehavrilla ...
In an option agreement announced today with MD Anderson Medical Center, ImmunoCellular Therapeutics (OTC: IMUC.OB) has acquired the rights to novel peptides that elicit a T-cell immune response against ...
... estimated date for data collection for the primary outcome of progression-free survival status at 5.5 months from the date of first dose. The estimated study completion date is Nov 2010. ImmunoCellular ...
48. RxNews Recap for Tuesday 11-17-09
(Home Page/Home Page)
... candidate in the treatment of Merkel cell carcinoma (MCC). Meaningful evidence of anticancer activity has been noted among the limited number of patients with MCC who have received IMGN901. ImmunoCellular ...
Griffin Securities issued an updated research report today on ImmunoCellular Therapeutics (OTC: IMUC.OB), which includes a price objective of $3.25 per share. Below are some highlights from the report, ...
... visit the News Room page for ImmunoCellular Therapeutics (OTC: IMUC.OB), which posted impressive updated Phase 1 survival data for its brain cancer vaccine (ICT-107) in late October and appears to be forming ...

Get Free Email and Phone News Alerts

* Your email address:
* Preferred Format:
* Enter the security code shown:
 
Home | Privacy Policy
© 2010 BioMedReports.com. All rights reserved